The Semliki Forest virus (SFV) expression system can be used to package recombinant RNA into infectious suicide particles. Such RNA encodes only the SFV replicase and the heterologous protein but no structural proteins of SFV, and it is thus deficient in productive replication. We demonstrate here that infection of C57BL/6 (H-2b) and BALB/c (H-2d) mice with recombinant SFV expressing the nucleoprotein (NP) of influenza virus (SFV-NP) resulted in efficient priming of influenza virus-specific CD8+ cytotoxic T-cell (CTL) responses. The generated CTLs lysed both homologous (A/PR/8/34) and heterologous (A/HK/68) influenza virus-infected, or peptide-coated, target cells to a similar degree as CTLs induced by wild-type influenza virus in a major histocompatibility complex class I-restricted fashion. As few as 100 infectious units of virus induced a strong CTL response. Induction of CTL by SFV-NP could also be achieved in CD4 gene-targeted mice, demonstrating the independence of the primary CTL response of CD4+ helper T cells. One immunization generated a CTL response that peaked after 1 week, and an additional booster injection generated a CTL memory, which was still detectable after 40 days. SFV-NP immunizations also generated high-titered IgG humoral responses that remained significant after several months. These results demonstrate that the recombinant SFV suicide system is highly efficient in antigen presentation and suggest that it may have a potential as a recombinant vaccine. CD8+ cytotoxic T lymphocytes (CTLs) have been demonstrated to be a major host defense mechanism against many viruses (1-4). During a viral infection, cytosolic antigens are proteolytically degraded into peptides, which are translocated into the lumen of the endoplasmic reticulum (ER) via ATPdependent transporters. In the ER, peptides associate with class I molecules of the major histocompatibility complex (MHC) and are then transported, along the normal exocytic pathway, to the cell surface for recognition by CD8+ CTLs. In contrast, exogenous antigens such as virus particles, bacteria, or soluble protein subunits are degraded into peptides within the endosomal compartment of the cell. Here they are loaded onto MHC class II molecules for presentation to CD4+ helper T cells (reviewed in refs. 5-8).
ABSTRACT
The Semliki Forest virus (SFV) expression system can be used to package recombinant RNA into infectious suicide particles. Such RNA encodes only the SFV replicase and the heterologous protein but no structural proteins of SFV, and it is thus deficient in productive replication. We demonstrate here that infection of C57BL/6 (H-2b) and BALB/c (H-2d) mice with recombinant SFV expressing the nucleoprotein (NP) of influenza virus (SFV-NP) resulted in efficient priming of influenza virus-specific CD8+ cytotoxic T-cell (CTL) responses. The generated CTLs lysed both homologous (A/PR/8/34) and heterologous (A/HK/68) influenza virus-infected, or peptide-coated, target cells to a similar degree as CTLs induced by wild-type influenza virus in a major histocompatibility complex class I-restricted fashion. As few as 100 infectious units of virus induced a strong CTL response. Induction of CTL by SFV-NP could also be achieved in CD4 gene-targeted mice, demonstrating the independence of the primary CTL response of CD4+ helper T cells. One immunization generated a CTL response that peaked after 1 week, and an additional booster injection generated a CTL memory, which was still detectable after 40 days. SFV-NP immunizations also generated high-titered IgG humoral responses that remained significant after several months. These results demonstrate that the recombinant SFV suicide system is highly efficient in antigen presentation and suggest that it may have a potential as a recombinant vaccine. CD8+ cytotoxic T lymphocytes (CTLs) have been demonstrated to be a major host defense mechanism against many viruses (1) (2) (3) (4) . During a viral infection, cytosolic antigens are proteolytically degraded into peptides, which are translocated into the lumen of the endoplasmic reticulum (ER) via ATPdependent transporters. In the ER, peptides associate with class I molecules of the major histocompatibility complex (MHC) and are then transported, along the normal exocytic pathway, to the cell surface for recognition by CD8+ CTLs. In contrast, exogenous antigens such as virus particles, bacteria, or soluble protein subunits are degraded into peptides within the endosomal compartment of the cell. Here they are loaded onto MHC class II molecules for presentation to CD4+ helper T cells (reviewed in refs. [5] [6] [7] [8] .
Although CTL responses can be generated against a variety of extracellular antigens such as lipopeptides (9, 10) , proteins incorporated into immunostimulating complexes (11) , and short synthetic viral peptides (12) (13) (14) (15) , strong cellular and humoral immune responses generally require priming with live virus (9, 16) . In effect, live vaccines are the most potent, but their use is often hampered for biosafety reasons. As alternatives, recombinant viral vectors (17) (18) (19) and naked DNA (20) (21) (22) (23) are gaining increased attention as means of expressing antigens.
Our approach is to use the Semliki Forest virus (SFV) replicon as a basis for developing recombinant RNA vaccines. SFV is an alphavirus consisting of a nucleocapsid with one copy of a single-stranded RNA molecule surrounded by an envelope containing the virus spike proteins (24) . SFV has several features that make it well suited for antigen expression. The RNA genome is infectious because of its positive polarity-i.e., naked genomic RNA is able to start an infection when introduced into the cytoplasm of a cell. The infecting RNA is self-replicating by coding for its own replicase, and the efficient replication can result in production of up to 108 protein molecules per cell. Replication occurs exclusively in the cytoplasm and cytopathogenic effects arise late in infection, leaving an extensive time window during which a high expression level is combined with negligible morphological changes.
We recently developed a vector system that allows for efficient expression of foreign coding sequences as parts of the SFV RNA replicon (25) (26) (27) . DNA of interest is cloned into a plasmid vector, which serves as a template for in vitro synthesis of recombinant RNA. The recombinant RNA is then cotransfected with helper RNA molecules into cells to become packaged into infectious virus particles (see Fig. 1 ). Only the recombinant RNA carries an encapsidation signal, and thus, in the absence of the viral structural genes, packaging produces recombinant particles that can infect cells only once, leading to one round of nonproductive replication. By separating the replicase and structural genes of the replicon, a high biosafety level is achieved. However, low levels of recombination between alphaviral RNAs have been observed (26, 28) , and therefore a mutant of the SFV helper was made that carries a mutation in the gene encoding one of the spike proteins, resulting in the production of noncleaved forms of that protein (26, 29) . In effect, such virus cannot infect new host cells unless first cleaved with exogenous protease. The use of this helper prohibits the spread of stray wild-type SFV and further increases the biosafety of the system (26) .
It was recently shown that recombinant Sindbis virus, another alphavirus, can express heterologous antigen to induce cellular and humoral responses in mice (19, 30 
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MATERIALS AND METHODS Cell Lines and Culture Conditions. The EL4 thymoma and B16 melanoma cells were derived from C57BL/6 mice (H-2b), and the P815 mastocytoma cell line was from DBA/2 mice (H-2d). The cells were cultured in RPMI 1640 medium supplemented with 5% fetal calf serum (FCS), 2mM L-glutamine, and antibiotics (penicillin and streptomycin). BHK-21 (baby hamster kidney) cells were grown in BHK medium supplemented with 5% FCS, 10% tryptose phosphate broth, 2 mM glutamine, 20 mM Hepes, and antibiotics.
Production of Infectious Suicide SFV. The plasmid pAPR501 containing the influenza PR8 NP gene was generously provided by P. Palese (The Mount Sinai Hospital, New York). The NP gene was isolated as an EcoRI fragment, blunt ended with Klenow fragment, and ligated into the Sma I site of pSFV1 (25) . Plasmid pSFV3-lacZ has been described (25) . In vitro made recombinant RNA was packaged into infectious SFV particles as described in detail (25, 26, 31) . To determine stock titers, BHK cells grown on coverslips were infected with serial dilutions of activated virus, and expression of antigen was visualized by indirect immunofluorescence (29) .
Detection of SFV-Expressed NP. Metabolic labeling of recombinant SFV-infected cells was done as described (31) . Labeled cells were scraped off the plate and lysed with Nonidet P-40 (NP-40) buffer (1% NP-40/50 mM Tris-HCl, pH 7.4/150 mM NaCl/2 mM EDTA/1 jig of phenylmethylsulfonyl fluoride (PMSF) per ml and cleared by centrifugation at 6000 rpm in a 5415 Eppendorf centrifuge. Pellet (nuclear) fractions were lysed in SDS lysis buffer (1% SDS/50 mM Tris-HCl, pH 7.4/150mM NaCl/2 mM EDTA/1 Ag of PMSF), sonicated for 15 min at 37°C, and then diluted with NP-40 lysis buffer. Immunoprecipitation was performed as described (29 (14) . Target cells were either infected with virus or incubated with peptide (50 ,uM) for 1.5 h at 37°C. After virus infection, cells were washed and further incubated for 2-4 h. The cells were then labeled with 51Cr (100 ,uCi; 1 Ci = 37 GBq; DuPont) for 1 h, washed, adjusted to the appropriate concentration and mixed with titrated effector CITLs in V-bottomed 96-well plates, and incubated for 4-6 h at 37°C. Supernatants were collected and radioactivity was measured in a y-counter. Results are expressed as percentage of specific lysis according to the formula % specific lysis = [(experimental release -spontaneous release)/(maximal release -spontaneous release)]cpm x 100. In all CTL experiments, one representative experiment of at least three with similar results is shown.
ELISA. Antibodies were detected by ELISA as described (40) . The recombinant NP antigen used was produced in the baculovirus expression system and was generously provided by Suezanne Parker (Vical, San Diego). Purified LacZ protein was from Boehringer Mannheim.
RESULTS
Expression of NP from the SFV Vector. We first used pulse-labeling to check expression of recombinant NP from the pSFV1 vector. BHK cells transfected with recombinant SFV expressing influenza NP (SFV-NP) RNA and labeled with
[35S]methionine showed a high level of NP expression (Fig.   1B) . Fractionation of the cell lysate showed that =50% of the NP protein had migrated to the nucleus within 60 min (Fig. 1B,   lanes 2 and 3) . The recombinant viral particles also generated significant CTL responses (Fig. 2B ). In the next experiments, 106 LU of SFV-NP was used for all subsequent immunizations. It should be noted that when the target cells were coated with an unrelated adenovirus ElA-specific peptide, no lysis occurred, demonstrating that SFV-NP-induced CTLs were specific against NP-expressing EL4 target cells. Similarly, mice primed with activated SFV-LacZ failed to elicit an anti-influenza CTL response (Fig. 2B) .
To determine whether the CTL response found could be generated in another haplotype strain of mice, BALB/c mice (H-2d) were infected with SFV-NP, SFV-LacZ, or PR8. As shown in Fig. 2C , SFV-NP could prime anti-influenza CTL responses also in the BALB/c strain. Target cells loaded with a control P815 peptide were not lysed. Again, SFV-LacZ did not induce any CTLs against influenza virus-infected or peptide-coated P815 target cells. The priming efficiency by SFV-NP was comparable to that by influenza virus also in this haplotype.
Characterization of the CTL Response. To define the nature of the cellular response, effector cell mixtures from SFV-NP immunizations were depleted of either CD4 or CD8 cells by using lysis by anti-CD4 or anti-CD8 monoclonal antibodies together with complement. Depletion of CD4 cells did not significantly change lysis levels, while these were completely abolished after CD8 depletion (data not shown). It was also interesting to evaluate the importance of CD4+ and CD8+ T cells for the SFV-NP-induced CTL responses. We immunized CD4-8+, CD4+8-, CD4-8-, and control C57BL/6 mice (all H-2b) with activated SFV-NP. The CTLs generated from CD4-8+ mutant mice showed a high cytolytic activity against homologous (PR8) and heterologous (HK68) influenza virusinfected or NP366-374-coated EL4 target cells. CD4+8-and CD4-8-mice gave no CTL response after immunization with SFV-NP (Fig. 3) .
CTL Memory. To measure the generation of CTL memory, two groups of BALB/c mice were infected with SFV-NP. The first group received only one priming dose, whereas the other The CTL activity elicited by one immunization of SFV-NP peaked at days 5 and 10 and declined close to background level at day 30 (Fig. 4) . The booster injection at day 14 resulted in a long-lasting CTL response, which was still significant at day 40.
Induction of a Humoral Response. To test for induction of antibodies, BALB/c mice were immunized at day 0 or at day 0 and day 14 with SFV-NP or SFV-LacZ, and sera were collected at various time points. A single immunization at day 0 resulted in the generation of high levels of anti-NP IgG (Fig.  5) . The booster injection enhanced the IgG response to NP 25-fold. Similar results were obtained with SFV-LacZ immunization. Antibodies to NP and LacZ were of the IgG type and were antigen specific as no cross-reactivity between these two antigens was seen (data not shown).
DISCUSSION
In this report, we have shown that recombinant, suicide SFV can be used to efficiently induce cellular and humoral anti-viral responses in two haplotype strains of mice. The generated CTLs were CD8+ and capable of recognizing virus-infected as well as peptide-coated target cells in a MHC class I-restricted manner. As few as 100 particles induced a significant CTL response, and this surprisingly high efficiency may relate to selective accumulation of the virus-expressed material in the immune system. In the recombinant SFV system, high levels of intracellular antigen are produced. In cell culture, under optimal condi- tions, a single cell may produce up to 0.1 ng of protein (25) . In vivo, such a high level is not expected, nor is it likely that all administered particles will infect a cell. Assuming that all particles do infect cells but produce only 10% of antigen compared to the amount seen in vitro, a dose of 100 IU could at best produce 1 ng of antigen. In vivo, this small amount of antigen must be processed and presented in a highly efficient way in order to generate the high levels of CTL activity and antibody responses seen. For the induction of a cellular immune response, lymphoid cells can respond either to the cells that primarily contain the foreign protein or to antigen presenting cells (APCs) that have taken up and processed material from such cells (41) . Both MHC class I and class II pathways can be entered by exogenous antigens, even if the classical MHC class I processing pathway is believed to be the operative only for cytosolic proteins (42) (43) (44) (45) . Thus, if recombinant SFV directly infects important APCs, then the classical class I pathway might be used for induction of a cellular immune response. Alternatively, material from infected cells might be further processed and presented in professional APCs. At present, we have no information on cells that are the primary targets for SFV after i.v. injection. However, it is likely that these include either important APCs, such as dendritic cells (DCs) or cells in the close proximity of APCs.
SFV-NP also induced memory responses. CTLs could be detected at least 40 days after immunization, and antibodies could be detected for at least 136 days. This may be surprising in view of the fact that the expression of antigen is transient only because of the suicide nature of the system. It has generally been assumed that maintenance of memory is dependent on persistence of antigen (46) (47) (48) . Since clearance of 35- Immunology: Zhou et aL SFV replication will be 'complete because of the selfdestructive features of the system, it is unclear how residual antigen could be sequestered, although antigen on the surface of DCs can persist for long periods of time (49) . Interestingly, recent data suggest that long-term T-cell memory may persist even in'the absence of the original antigen (50) (51) (52) .
It has previously been shown that mice lacking CD4+ cells (32, 53) or MHC class II antigens (54) are able to mount virtually normal CTL responses against infecting viruses, although the presence of some helper T-cell function in such cases cannot totally be excluded (55) . It has also been shown that CD8 is needed for the maturation and positive selection of class I MHC-restricted CTLs, as cytotoxic responses are dramatically decreased in CD4-mice (33, 34) . Our results suggest that CD4+ T cells do not play a central role for the primary induction of NP-specific C1Ls after immunization with-SFV-NP. However, clonal expansion and memory development in the absence of T-cell help was not investigated.
The SFV expression system may have several advantageous features useful for immunological stimulation and vaccination purposes. Due to the self-replicating nature of the RNA molecule, high levels of antigen expression can be achieved. This coupled to an efficient in vivo expression strategy could mean that only small amounts of virus are needed to achieve a good vaccination effect. Moreover, with the exception of small amounts ofviral replicase, no other vector proteins are produced. This is an additional advantage when repeated immunizations with the same vectors are needed. A high level of biosafety is also achieved since the recombinant virus particles infect cells only once. Altogether our results demonstrate that the recombinant SFV suicide system is highly efficient in antigen presentation and suggest that it may have a potential as a recombinant vaccine.
We are indebted to Drs. Tak Mak, Innocent Mbawuike, Peter Palese, and Suezanne Parker for providing materials used in this study.
We also would like to thank Dr. Hans-Gustaf Ljunggren for a critical reading of the manuscript and Ms. Anna-Lena Hammarin for growing the influenza virus. This work was supported by the Swedish Cancer Society (M.J.), the Swedish Medical Research Council (P.L.), the Swedish Research Council for Engineering Sciences (P.L.), the Astra Pharmaceutical Company (M.J.), and the Karolinska Institute (M.i. and P.L.). X.Z. and P.B. are recipients of the graduate student scholarship program at the Karolinska Institute.
